NCT03466021View on ClinicalTrials.gov

Effects of Liraglutide in Chronic Obstructive Pulmonary Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

May 31, 2020

Study Completion Date

May 31, 2020

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

Liraglutide

Initially 0.6 mg daily, increasing weekly with 0.6 mg, until 3.0 mg is reached.

DRUG

Placebo

Matching injection

Trial Locations (2)

6700

Hospital of South West Jutland, Esbjerg

7100

Lillebaelt Hospital, Vejle

All Listed Sponsors
lead

Claus Bogh Juhl

OTHER

NCT03466021 - Effects of Liraglutide in Chronic Obstructive Pulmonary Disease | Biotech Hunter | Biotech Hunter